Article

Live Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer

In an upcoming broadcast, Joyce O'Shaughnessy, MD, Shanu Modi, MD, and Anne O’Dea, MD will discuss the approach and goals of the management of certain patients with HER2+ metastatic breast cancer (mBC) and take a deeper look at the burden and unmet needs of the disease. Additionally, they will discuss a second line treatment option for HER2+ mBC.

To obtain expert perspective and learn about the efficacy and safety data of this treatment option, watch the live broadcast on 6/16/2022. To register for the event, visit https://studio.mjhassoc.com/reach/2L-HER2Pos-mBC.

PP-US-ENB-1270 05/22

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.